Skip to main content
Download PDF

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

BMC Cancer volume 22, Article number: 375 (2022) Cite this article

Abstract

Background

In patients with bone metastatic castration-resistant prostate cancer (bmCRPC) on systemic treatment, it is difficult to differentiate between continuous rise of prostate specific antigen (PSA) representing progression, and PSA-surge, which is followed by clinical response or stable disease. The purpose of this study was to evaluate the prognostic value of dynamic changes of alkaline phosphatase (ALP) and lactic acid dehydrogenase (LDH) levels as a predictor of clinical efficacy or therapeutic resistance of patients who do not show a sufficient initial PSA decline of ≥50% from baseline during early therapy with Enzalutamide.

Methods

Forty-eight men with bmCRPC on Enzalutamide 07/2010-09/2019 with initially rising PSA were analyzed. We monitored PSA, LDH and ALP at week 0, 2, 4, and every 4 weeks thereafter and analyzed the correlation between ALP rising at 12 weeks with or without LDH-normalization and the association with survival. For this we used Kaplan Meier analysis and uni- and multivariate cox-regression models.

Results

In Kaplan-Meier analysis, ALP rising at 12 weeks with or without LDH-normalization was associated with significantly worse median progression-free survival (PFS) of 3 months vs. 5 months (Log rank P = 0.02) and 3 months vs. 5 months (P = 0.01), respectively and overall survival (OS) with 8 months vs. 15 months (P = 0.02) and 8 months vs. 17 months (P < 0.01). In univariate analysis of PFS, ALP rising at 12 weeks alone, ALP rising at 12 weeks without LDH-normalization and application of Enzalutamide after chemotherapy showed a statistically significant association towards shorter PFS (hazard ratio (HR): 0.51, P = 0.04; HR: 0.48, P = 0.03; HR: 0.48, P = 0.03). Worse OS was significantly associated with ALP rising at 12 weeks alone, ALP rising at 12 weeks without LDH-normalization, and application of Enzalutamide after chemotherapy (HR: 0.47, P = 0.02; HR: 0.36, P < 0.01; HR: 0.31, P < 0.01). In multivariate analysis only the application of Enzalutamide after chemotherapy remained an independent prognostic factor for worse OS (HR: 0.36, P = 0.01).

Conclusions

Dynamic changes of ALP (non-rise) and LDH (normalization) under therapy with Enzalutamide may be associated with clinical benefit, better PFS, and OS in patients with bmCRPC who do not show a PSA decline.

Peer Review reports

Background

Prostate cancer (PCa) is the most frequent type of cancer and the second most common reason of cancer-related deaths in men [1].

Mostly, metastatic disease develops from locoregional lymph nodes followed by the bones und ultimately visceral metastases [2]. Bones are the most common metastatic site in advanced PCa and associated with worse outcome than in patients with lymph node metastasis only [2].

Androgen deprivation therapy (ADT) is considered as standard treatment for metastatic disease [3]. When cancer cells no longer respond to ADT despite achieving castration levels of testosterone and prostate specific antigen (PSA) rises, PCa has become castration-resistant and is known as (metastatic) castration-resistant prostate cancer (mCRPC). Metastastic CRPC is the most advanced stage of PCa and is responsible for the vast majority of prostate cancer related deaths [4].

Patients with bone-metastatic CRPC (bmCRPC) are at higher risk of developing complications such as fractures according to their metastatic burden.

Patients with mCRPC can be treated with chemotherapy (Docetaxel, Cabazitaxel), next-generation androgen receptor-targeted agents (ARTAs) (Abiraterone or Enzalutamide), Sipuleucel-T, Radium-223, Olaparib or Rucaparib [5,6,7,8,9,10,11,12,13,14].

Enzalutamide is an oral 2nd generation androgen receptor (AR) antagonist which binds to the AR with higher relative affinity than for example the 1st generation AR antagonist bicalutamide. By suppressing nuclear translocation of the AR and its binding to coactivating proteins and DNA, Enzalutamide induces apoptosis [15].

Enzalutamide is approved for the treatment of asymptomatic or mildly symptomatic mCRPC patients in the pre-chemotherapy setting and after taxane treatment [13, 14]. It prolongs overall survival (OS) in both, mCRPC and in non-metastatic CRPC [13, 14, 16].

The determination whether therapy is efficacious is a challenging aspect for clinicians treating bmCRPC patients. Computer tomography (CT) imaging, magnetic resonance imaging (MRI) and bone scintigraphy can help to provide answers [17]. However, changes in the size of bone metastases are difficult to detect under early treatment. Bone-flare may occur representing detection of initially occult bone metastasis which become visible by increased activity of osteoblasts and hence osteosclerosis after response to treatment. This condition can be falsely interpreted as progressive disease (PD) [18]. In this setting, the clinical condition of the patient (e.g. Eastern Cooperative Oncology Group performance status (ECOG)) and the conventional biomarker PSA are commonly used to differentiate between treatment response and progress. Additionally, lactic acid dehydrogenase (LDH), alkaline phosphatase (ALP) and circulating tumor cells (CTCs) are under discussion to improve the selection of patients with superior benefit from Enzalutamide treatment [19,20,21,22].

PSA is widely used as screening marker for prostate cancer and for treatment monitoring in the setting of mCRPC. Data suggest that changes of PSA-values have prognostic potential and might help deciding whether to continue or stop therapy [23]. On the one hand, a PSA decline under therapy with Enzalutamide is associated with better OS, progression-free survival (PFS) and pain response [24, 25]. On the other hand, rising PSA-values alone are not a criterium for progression. Additionally, rising values under early treatment may occur before a delayed decline becomes evident. This phenomenon is called PSA-surge and characterized by rising PSA-levels after therapy initiation followed by a decline within the first 12 weeks of treatment [23, 26, 27]. Consequently, patients who do not show a PSA-decline ≥50% are difficult to evaluate. Therefore, the early differentiation between PSA-surge, potential bone-flare, and PD is important and further information is needed to distinguish between a true progression and a surge/flare.

Changes in CTC enumeration can prognosticate outcome of patients with mCRPC. Therefore, these changes are under discussion to support monitoring of treatment success [22]. Unfortunately, CTC-detection is not part of the clinical routine and not broadly available and therefore, probably not a suitable marker for repeated evaluation of response to therapy in routine medicine.

LDH and ALP have been shown to have prognostic potential as biomarkers. If found within normal range or if normalizing under therapy, they are associated with better survival in mCRPC-patients [19,20,21].

LDH is an unspecific biomarker. While rising LDH levels suggest poor prognosis, LDH-normalization suggests response to the therapy and indicates towards increased OS [28].

In contrast, ALP is more specific in bmCRPC and can provide prognostic information [20, 21, 29].

Furthermore, a phenomenon called ALP-bouncing, defined as a rising ALP during the first 2–8 weeks after starting therapy and followed by a decline to baseline levels or below showed to be associated with response and outcome in bmCRPC treated with Abiraterone [20]. Other data confirmed this finding; hence, ALP could be a promising biomarker during the first weeks of therapy helping to decide whether to continue or stop therapy early [20].

For LDH-normalization, ALP-bouncing, and PSA-decline as well as the combination of these biomarkers it was shown that these may help identifying patients with good response to therapy with Enzalutamide [30]. According to these results, showing that changes of LDH and ALP add information in patients with or without significant PSA-decline, we intended to study the prognostic potential of these markers in patients with questionable response to therapy because of an insignificant PSA-decline.

Therefore, we studied patients receiving Enzalutamide without initial PSA-response and evaluated LDH and ALP levels as potential prognostic factors of survival outcomes during the remaining study period.

Methods

Patient population and outcome evaluation

We retrospectively reviewed 99 mCRPC patients who received Enzalutamide at the Department of Urology of the University Hospital Münster, Germany between 07/2010 and 09/2019.

Prior to any study related activity, the patients had given written informed consent before participating and the ethics committee-approval was granted. (Aktenzeichen: 2007-467-f-S) The study was carried out according to the requirements of the declaration of Helsinki.

Since ALP is irrelevant when bone metastases are missing, we excluded patients with non-bone-metastatic disease. Further, we excluded the patients with a significant PSA-decline (≥50%) to determine the benefit of changes of ALP and LDH when PSA is leading to non-straightforward information. Finally, 48 patients with a complete data set were evaluable for analysis.

All patients received Enzalutamide according to the approved label in a pre-chemotherapy setting (n = 21 (43.8%)) or after docetaxel chemotherapy setting (n = 27 (56.3%). Twelve patients (25.0%) received Enzalutamide in a pre-Abiraterone setting. Thirty-four patients (70.8%) were on a stable dose of a bone targeting agent (zoledronic acid n = 17 (35.4%) or denosumab n = 17 (35.4%)) for at least three months before initiation of Enzalutamide treatment. The other men did not receive bone health agents at all.

Directly prior to the start of Enzalutamide, blood was drawn for baseline analysis. In addition, we evaluated ECOG and pain level. The follow-up examinations were performed after two and four weeks and every 4 weeks thereafter. PSA, ALP and LDH levels in serum samples were immediately measured on the same day.

Patients were grouped as with normal LDH (all values in the range of normal during the whole study period) or patients with elevated LDH levels prior to start of therapy with Enzalutamide and conversed to normal levels and stayed there during the remaining study period.

ALP-bouncing was previously defined as a rising ALP during the first 2–8 weeks of therapy followed by a decline to or below pre-treatment levels. Rising ALP was defined as any increase during the first 12 weeks of Enzalutamide.

The assessment of current response status took place at the routinely planned visits. For the determination of response status, ECOG, presence of pain, laboratory constellations as well as imaging were taken into account. Clinical progression was defined as symptomatic progression (worsening or new prostate cancer-related symptoms). PSA progression was defined according to the ‘Prostate Cancer Working Group 3 (PCWG3) criteria’ as a confirmed increase of 25% or greater and a value of more than 2 ng/ml from baseline beyond 12 weeks [17]. When no clinically and biochemically progression was suspected, imaging was not performed routinely. When progression was asumed, soft tissue metastases were evaluated by CT- and/or MRI-scans of thorax, abdomen and pelvis. Bone metastases were assessed by bone scans. In 36 patients imaging was performed and PD was defined according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria for cross-sectional imaging and by PCWG3 criteria for bone scans [17, 31].

Statistical methods

We used SPSS statistics V.26 (IBM Inc., Armonk, NY) for statistical assessment.

The descriptive statistics are reported as medians with interquartile ranges (IQR) or 95% confidence intervals (CI) for continuous variables and as frequencies and populations for categorical variables.

Regarding the differences between ALP-increase vs. no increase, ALP-bouncing vs. no bouncing and LDH-normalization vs. no normalization as well as the combination of these biomarker changes, survival analyses were performed using Kaplan-Meier-Analyses (KMA). The definition of PFS included biochemical and radiographic progression according to the definition of PCWG3 and RECIST 1.1. OS was defined as the interval from treatment initiation until death from any cause.

For univariate (UV) and multivariate (MV) analyses of the significance of survival outcomes for the different biomarkers we used Cox regression models.

Hazard ratios (HR) are given with 95% CI. All reported p-values are two-sided and statistical significance was assumed with a P < 0.05.

Considering OS, statistical power was estimated 13.36% for LDH-normalization, 41.18% for rising ALP at 12 weeks and 49.7% for rising ALP at 12 weeks without LDH-normalization. For the analysis of PFS it was 12.43%, 33.12% and 29.21%, respectively.

Results

Characteristic of the study group

Descriptive characteristics of the cohort are presented in Table 1. The median age of our patients was 70.5 years (IQR, 63.0-75.8 years). At start of Enzalutamide, lymphonodal metastases were present in 38 patients (79.2%) and visceral metastases in 13 patients (27.1%). A Gleason-Score of ≥ 8 at initial diagnosis was present in 23 patients (47.9%). Considering ECOG performance status, 24 (50.0%) of our patients were asymptomatic and fully active (ECOG grade 0) while 19 patients (39.6%) were ECOG grade 1, 4 (8.3%) ECOG grade 2, and 1 (2.1%) ECOG grade 3, respectively. The proportions of patients in either pre- or post-chemotherapy setting showing rising ALP at 12 weeks, LDH-normalization, or ALP rising at 12 weeks, without LDH-normalization are given in Table 1.

The median follow-up was 12 months (IQR, 7.0-19.3 months). The median time on Enzalutamide was 5 months (IQR, 3.0–9.0 months). Median baseline levels were 125.3 ng/ml (IQR, 51.2-470.8) for PSA, 274.0 U/l (IQR, 232.0-352.0) for LDH and 155.0 U/l (IQR, 97.8-304.3) for ALP. A PSA-surge occurred in 10 patients (20.8%). Only three of them (30%) had a PD, seven patients (70%) subsequently responded to Enzalutamide. Three patients (6.3%) showed to have an ALP-bouncing (Table 1).

Table 1 Characteristics of patients with bmCRPC on Enzalutamide without PSA-response (decline ≥ 50%)
Full size table

Kaplan-Meier survival analysis

The Kaplan-Meier analyses for PFS and OS are given in Figs. 1 and 2. Considering survival of the overall population, median PFS resulted in 3 months (95%CI, 2.0–4.0 months), median OS in 13 months (95%CI, 10.9–15.1 months). Regarding subgroups, PFS and OS worsen with rising ALP at 12 weeks alone and in combination of rising ALP at 12 weeks without LDH-normalization. The changes are associated with a shorter PFS of 3 months (95%CI, 2.4–3.6) vs. 5 months (95%CI, 3.8–6.2) (Log rank P = 0.02) and 3 months (95%CI, 2.4–3.7) vs. 5 months (95%CI, 3.0–7.0) (P = 0.01), respectively.

The analysis of OS showed similar results with 8 months (95%CI, 5.1–10.9) vs. 15 months (95%CI, 11.5–18.5) (P = 0.02) for ALP rising at 12 weeks, 8 months (95%CI, 7.0–9.0) vs. 17 months (13.3–20.7) (P < 0.01) for ALP rising at 12 weeks without LDH-normalization.

LDH-normalization did not predict PFS with 2 months (95%CI, not estimable) vs. 3 months (95%CI, 2.0–4.0) (P = 0.86) and the OS with 17 months (95%CI, 8.7–25.3) vs. 12 months (95%CI, 8.4–15.6) (P = 0.24).

Fig. 1
figure 1

Kaplan-Meier analyses of overall survival of mCRPC patients treated with Enzalutamide who do not show a sufficientent initial PSA decline ≥ 50%

a) with and without LDH normalization

b) with and without ALP rising at 12 weeks independent of LDH dynamics, and

c) with and without ALP rising at 12 weeks, without LDH normalizastion

Full size image
Fig. 2
figure 2

Kaplan-Meier analyses of progression free survival of mCRPC patients treated with Enzalutamide who do not show a sufficientent initial PSA decline ≥ 50%

a) with and without LDH normalization

b) with and without ALP rising at 12 weeks independent of LDH dynamics, and

c) with and without ALP rising at 12 weeks, without LDH normalizastion

Full size image

Changes of LDH and ALP as prognostic markers

In univariate (UV) analysis, parameters with unfavorable changes were associated with a worse outcome. These results are displayed in Table 2. In the analysis of PFS, ALP rising at 12 weeks alone, ALP rising at 12 weeks without LDH-normalization and the application of Enzalutamide after chemotherapy showed a statistically significant association towards shorter PFS (HR: 0.51 (95%CI, 0.3-1.0); P = 0.04; HR: 0.48 (95%CI, 0.3–0.9); P = 0.03; HR: 0.48 (95%CI, 0.3–0.9); P = 0.03).

Worse OS was significantly associated with ALP rising at 12 weeks alone, ALP rising at 12 weeks without LDH-normalization, and the application of Enzalutamide after chemotherapy (HR: 0.47 (95%CI, 0.3–0.9); P = 0.02; HR: 0.36 (95%CI, 0.2–0.7); P < 0.01; HR: 0.31 (95%CI, 0.2–0.7); P < 0.01).

Table 2 Univariate analyses of significant biomarkers for PFS and OS in 48 bmCRPC-patients on Enzalutamide-therapy without PSA-response
Full size table

The results displayed in Table 3 show that in multivariate (MV) analysis, regarding PFS, none of the parameters remained an independent prognostic factor for worse PFS. Within the analysis of OS, only the application of Enzalutamide after chemotherapy showed an independent and statistically relevant difference towards shorter OS (HR 0.36 (95%CI, 0.2–0.8); P = 0.01) .

Table 3 Multivariate analyses of biomarkers for PFS and OS in 48 bmCRPC-patients on Enzalutamide-therapy without PSA-response
Full size table

Discussion

There are several clinical and biochemical prognostic factors that can be captured prior to treatment or during very early treatment that are associated with survival outcomes. PSA, PSA kinetics, LDH, ALP, hemoglobin, performance status, presence of metastases, presence of pain, CTCs, Gleason Score, age, and albumin have been under discussion to be prognostic in mCRPC [32,33,34].

However, there are some limitations considering these factors. Clinical factors (ECOG and pain level) are difficult to compare since the determination of those markers is highly dependent on both the subjective reporting of the patient and the evaluator. Further, many patients are only mildly symptomatic or even asymptomatic, thus, a change of symptoms to the better cannot occur in these patients. Hemoglobin, age, and LDH and albumin are not specific for prostate cancer.

Specific biomarkers which are easily available and might help to prognosticate treatment outcomes for patients under early therapy with Enzalutamide are therefore essential but currently lacking [30].

CTCs are specific and an increase under therapy with Enzalutamide was shown to be associated with worse PFS and OS. Additionally, a prospective, multicenter study showed that CTC enumeration is an independent prognostic factor [35, 36]. Another study showed that CTC dynamics are more prognostic than post-therapy changes in PSA [36]. But CTC-assays are expensive and not easily available. This makes the use in clinical routine difficult.

To optimize treatment, easily available and affordable biomarkers like PSA, LDH and ALP would be better options in wide clinical routine.

PSA is already widely used as a biomarker in prostate cancer, in mCRPC particularly, for treatment monitoring. A decrease after therapy initiation can be interpreted as a surrogate for expected response. Especially a decrease of PSA-levels by ≥50% is regarded as threshold of biochemical response to a given treatment [17]. Despite the given fact, that declining PSA-values in most cases indicate response to therapy, a transient increase of PSA may occur not due to a true progression but by circulatory release of PSA during response of a newly started therapy, as well. Furthermore, some patients only show stabilization of PSA-values and do not show a progression either [37]. Hence, the group of patients that shows a PSA-decline < 50% is more difficult to evaluate and might even be misinterpreted as therapeutic failure [38]. A PSA-surge can be regularly observed [23, 26, 27]. This clinically difficult situation is especially demanding in mildly- or asymptomatic patients, when PSA is the only clinical measure available.

For bone metastatic disease, a phenomenon in imaging, comparable to an initial PSA-increase, a bone-flare, is known. This can occur when imaging is performed during the first three to six months of therapy and shows a pseudoprogression by visualized hitherto occult metastases and represents response to treatment but is often time mistaken for pressive disease [18, 39,40,41].

In our study 10 patients (20,8%) showed a PSA-surge with rising PSA-levels after therapy initiation that started to decline after 12 weeks of treatment. Out of these patients, only three (30%) ultimately showed a progressive disease at any time of evaluation. This finding underlines guideline recommendations saying that changes in PSA under treatment should not be used alone when deciding whether to continue treatment [17].

In the worst scenario a misinterpreted rising PSA could lead to either premature termination of a working treatment or on the other hand to a shift to the next line in therapy when it is too late and a patient is no more eligible to receive for example chemotherapy. Considering our patients, seven (70%) ultimately responded to Enzalutamide and would have been imperiled by terminating treatment too early in case of overestimating the value of PSA or in the case of a lack of other criteria. We tried to find a biomarker to differentiate between patients with a PSA-surge and those with a true progression by separating these 10 patients into two groups. Probably due to a small group size of only three patients with progressive disease, statistical analysis did not result in meaningful differences. Though a number of only 10 patients with PSA-surge was not sufficient for statistical analysis, our result emphasizes the statement that we need other biomarkers, alone or in addition to accepted ones, which help to distinguish between response and progression in the given scenario. Therefore, we evaluated additional and easily available biomarkers for prognostication of outcome in this highly selected population without significant PSA-decline (< 50%).

LDH is a very unspecific biomarker for malignancies in general and for inflammatory diseases [42]. Nevertheless, rising LDH levels are associated with worse prognosis, whereas normalization can be considered a marker of response to therapy and better OS in cancer patients [28].

ALP is more specific, and bone related and can provide prognostic information for men with PCa [20, 21, 29]. In a metaanalysis of unselected PCa cohorts, elevated ALP was associated with worse PFS and OS [43]. According to other data, patients in the setting of newly diagnosed prostate cancer, can be divided in three different risk groups, low corresponds to zero risk factors, intermediate to one or to two risk factors and high corresponds with three risk factors depending on the changes of ALP, PSA and hemoglobin (Hb) under therapy predicting PFS and OS. [44].

In recent studies, ALP-bouncing was found to be prognostic for better survival outcomes. It was defined as a rising ALP during the first 2–8 weeks after starting therapy and followed by a decline to or below pre-treatment and baseline levels. The authors concluded that it might be a promising prognostic biomarker in patients with bmCRPC [20].

Further studies suggested that LDH-normalization, ALP-bouncing, PSA-decline, and the combination of these three biomarkers could help identifying patients with a good response to therapy with Enzalutamide [30]. This study evaluated patients with bmCRPC with or without significant PSA-decline.

The purpose of this study was to evaluate the prognostic ability of dynamic changes of ALP and LDH levels as a prognostic factor of PFS and OS in patients with bmCRPC that do not show a sufficient PSA-decline of ≥50% of the initial value in the early therapy with Enzalutamide. In our cohort, we evaluated several dynamic biomarker changes. Considering LDH-normalization or ALP-bouncing alone we were not able to show that these, usually regarded as favorable, can be considered as prognostic factors for better PFS or OS.

LDH-normalization but also a decline under therapy with Enzalutamide cannot be used as a predictor of treatment success for our cohort. The Kaplan-Meier analysis did not reveal significantly better PFS or OS. The non-specific nature of LDH in the bone-metastases enriched population in our study may be part of the reasons for this finding.

With respect to the very small number of only three patients with ALP-bouncing (6.3%) in our study, we concluded that the phenomenon is very rare, at least in our selected cohort with only patients without significant PSA-decline. Therefore, we could not evaluate this criterion.

However, we found in UV that sole ALP rising at 12 weeks and ALP rising at 12 weeks without LDH-normalization under therapy with Enzalutamide are prognostic factors of poor PFS and OS in patients with bmCRPC. Still, in our view, the favorable results considering the combination of rising ALP without LDH-normalization, should not be overinterpreted. On the one hand, we could only show statistical relevance in UV whereas MV did not confirm these results and, on the other hand, probably, ALP accounts for most of this effect. Hence, ALP could be a useful biomarker to differentiate between PSA-surge and PSA-progression in bmCRPC patients during the treatment with Enzalutamide.

Translating our results into clinical routine and looking at the extreme outliners, there might be a group of patients benefiting from a change of therapy. Six of the 21 patients with rising ALP-values showed extreme changes which, from a retrospective view, could have benefited from treatment adjustment. Those patients had ALP-values that, after 12 weeks, doubled at least. Survival was were extremely short in this group, PFS was 2.5 (2-4.25) and OS 6.5 (4.75-8) months. In the context of the whole study cohort, PFS was 3 months for patients with rising ALP after 12 weeks of treatment, OS was 8 months for this group. Patient without rising ALP had a PFS of 5 and an OS of 17 months.

Our study is limited due to its relatively small cohort of only 48 patients recruited in a single center and by problems inherent to the retrospective approach, e.g. a missing validation cohort. We separated these patients into subgroups, by which the group sizes became even smaller. This is probably one reason why we were not able to demonstrate significant results. Therefore, larger prospective trials are needed to validate the significance of our findings.

Nonetheless, our results are clinically important. In clinical practice it is difficult to differentiate between a continuous rise, that would represent progression, and a PSA-surge which is followed by a response or stable disease. ALP is easily accessible and can help us to make the right decision in individual cases.

Conclusions

Dynamic changes of ALP and LDH (non-rise and normalization) under therapy with Enzalutamide may be associated with clinical benefit and better PFS and OS in patients with bmCRPC who do not show a significant PSA decline. Potentially ALP is the more relevant parameter since it is specific for bone metastatic disease and LDH-normalization alone could not show a trend towards improved PFS or OS.

Availability of data and materials

Analyzed data are stored at the Department of Urology, University hospital Münster, Germany and are available on reasonable request if not already included in this article.

Abbreviations

PCa:

Prostate cancer

mCRPC:

Metastatic castration resistant prostate cancer

bmCRPC:

Bone metastatic castration resistant prostate cancer

ADT:

Androgen-deprivation therapy

LDH:

Lactic acid dehydrogenase

PSA:

Prostate specific antigen

ALP:

Alkaline phosphatase

AR:

Androgen receptor

ECOG:

Eastern cooperative oncology group performance status

CTC:

Circulating tumor cells

PD:

Progressive disease

OS:

Overall survival

PFS:

Progression-free survival

CT:

Computer tomography

MRI:

Magnetic resonance imaging

IQR:

Interquartile range

PCWG 3:

Prostate Cancer Working Group 3

RECIST:

Response Evaluation Criteria in Solid Tumours

CI:

Confidence interval

KMA:

Kaplan Meier analysis

UV:

Univariate

MV:

Multivariate

HR:

Hazard ratio

Hb:

Hemoglobin

ARTAs:

Androgen receptor-targeted agents

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer. Future Oncol. 2010;6(5):823–36.

    Article  PubMed  Google Scholar 

  3. Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75(3):410–8.

    Article  PubMed  Google Scholar 

  4. Ma X, Huang J. Predicting clinical outcome of therapy-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11090–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.

    Article  CAS  PubMed  Google Scholar 

  6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  7. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.

    Article  CAS  PubMed  Google Scholar 

  8. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  CAS  PubMed  Google Scholar 

  9. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–46.

    Article  CAS  PubMed  Google Scholar 

  10. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  CAS  Google Scholar 

  11. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091–102.

    Article  PubMed  Google Scholar 

  12. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020;38(32):3763–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

    Article  CAS  PubMed  Google Scholar 

  14. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–18.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Taleb BA. Tumour flare reaction in cancer treatments: a comprehensive literature review. Anticancer Drugs. 2019;30(9):953–8.

    Article  CAS  Google Scholar 

  19. Mori K, Kimura T, Onuma H, Kimura S, Yamamoto T, Sasaki H, et al. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Prostate. 2017;77(10):1144–50.

    Article  CAS  PubMed  Google Scholar 

  20. Mikah P, Krabbe LM, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, et al. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer. 2016;16:214.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30(5):607–13.

    Article  CAS  PubMed  Google Scholar 

  22. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.

    Article  PubMed  CAS  Google Scholar 

  23. Schlack K, Krabbe LM, Fobker M, Schrader AJ, Semjonow A, Boegemann M. Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. Int J Mol Sci. 2016;17(9):1520.(9).

    Article  PubMed Central  CAS  Google Scholar 

  24. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–704.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Armstrong AJ, Saad F, Phung, Dmuchowski C, Shore ND, Fizazi K, et al. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017;123(12):2303–11.

    Article  CAS  PubMed  Google Scholar 

  26. Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, et al. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017;15(2):320–5.

    Article  PubMed  Google Scholar 

  27. Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.

    Article  PubMed  Google Scholar 

  28. Faloppi L, Bianconi M, Giampieri R, Sobrero A, Labianca R, Ferrari D, et al. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget. 2015;6(33):35087–94.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, et al. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. Eur Urol. 2015;68(1):42–50.

    Article  PubMed  Google Scholar 

  30. Schlack K, Krabbe L-M, Rahbar K, Isenberg K, Semjonow A, Schrader AJ, et al. ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. Translational Andrology and Urology. 2021:doi: https://doi.org/10.21037/tau-20-1117.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232–7.

    Article  PubMed  Google Scholar 

  33. Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27(3):454–60.

    Article  CAS  PubMed  Google Scholar 

  34. Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, et al. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2017:S1558-7673(17)30211–2.

    Google Scholar 

  35. De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, et al. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. Prostate. 2018;78(6):435–45.

    Article  PubMed  CAS  Google Scholar 

  36. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10(3):233–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, et al. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2019;22(4):588–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014;50(9):1617–27.

    Article  PubMed  Google Scholar 

  39. Roghmann F, Antczak C, McKay RR, Choueiri T, Hu JC, Kibel AS, et al. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015;33(1):17 e9- e8.

    Article  PubMed  Google Scholar 

  40. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Johns WD, Garnick MB, Kaplan WD. Leuprolide therapy for prostate cancer. An association with scintigraphic “flare” on bone scan. Clin Nucl Med. 1990;15(7):485–7.

    Article  CAS  PubMed  Google Scholar 

  42. Terragni R, Morselli-Labate AM, Vignoli M, Bottero E, Brunetti B, Saunders JH. Is Serum Total LDH Evaluation Able to Differentiate between Alimentary Lymphoma and Inflammatory Bowel Disease in a Real World Clinical Setting? PLoS One. 2016;11(3):e0151641.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Li D, Lv H, Hao X, Hu B, Song Y. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manag Res. 2018;10:3125–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, et al. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Sci Rep. 2019;9(1):12071.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Daniel Rahr and Moritz Fabian Danzer for their helpful advice.

Funding

Open Access funding enabled and organized by Projekt DEAL. This research received no external funding.

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital Muenster, Münster, Germany

    Renata Poteska, Axel Semjonow, Andres Jan Schrader, Martin Boegemann & Katrin Schlack

  2. Department of Nuclear Medicine, University Hospital Muenster, Münster, Germany

    Kambiz Rahbar

  3. University Hospital Muenster, Westdeutsches Tumorzentrum, Münster, Germany

    Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Boegemann & Katrin Schlack

  4. Department of Urology, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149, Muenster, Germany

    Katrin Schlack

Authors
  1. Renata Poteska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kambiz Rahbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Axel Semjonow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andres Jan Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Boegemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katrin Schlack
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.P. concept of the study, methodology, formal analysis, investigation, data curation, writing, original draft preparation, visualization, review, editing; K.R. writing, review, editing; A.S. validation, writing, review, editing; A.J.S. validation, writing, review, editing; M.B. concept of the study, validation, supervision, project administration, writing, review, editing; K.S. concept of the study, methodology, validation, formal analysis, visualization, supervision, project administration, writing, review, editing. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Katrin Schlack.

Ethics declarations

Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki. Retrospective analysis of the entire cohort of patients with mCRPC treated with Enzalutamide was approved by the local ethics committee (No. 2007-467-f-S and later amendments, Ethikkommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster).

Consent for publication

Not applicable.

Competing interests

Author RP declares no conflicts of interest.

Author KR received consulting and lectureship honoraria from Bayer, ABX, ABR, CRO, Janssen Cilag, AAA and SIRTEX.

Author AS has received research grants from German Cancer Aid, speaker honoraria from Janssen and Ipsen, research collaboration with Philips Healthcare and Proteomedix, and owns a patent “Characterization of primary tumors” (039PCT0735).

Author AJS received research grants form Astellas and Janssen Cilag and honoraria for advisory-roles from Janssen Cilag, Astellas and Bayer.

Author MB has received honoraria for advisory-roles from Janssen Cilag, Astellas, Sanofi and Bayer.

Author KS has received honoraria for advisory-roles from Amgen, AstraZeneca, Bayer, Janssen Cilag and Ilpsen.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poteska, R., Rahbar, K., Semjonow, A. et al. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. BMC Cancer 22, 375 (2022). https://doi.org/10.1186/s12885-022-09483-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-022-09483-7

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us